Medtronic, Inc. (MDT) PT Raised to $94 at BMO Capital on 4Q Beat; 'Strength Across Franchises'

BMO Capital raised its price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $87.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.

Analyst Joanne Wuensch notes the company delivered fourth quarter earnings per share and revenues above consensus expectations, as management has benefited from robust operating leverage resulting in strength across franchises.

You May Also Be Interested In

• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Citi upgrades AMD to buy with $575 price target ahead of Q4 earnings